Drug Efficacy Study Implementation (DESI) programDonnatal, Concordia's #1 drug, because of its 800% price increase since it was bought, sold, resold between pharma companies, is under the FDA's DESI program.
This is a drug under attack and nobody will show any love to Concordia or owners (shareholders) if a generic is fact tracked or a substitute is pushed through by the FDA.
GIven the intense political scrutiny here, if I was head of the FDA, I would make it my mission to have a quick win against pharmas that price gouge patients in need.
Shareholders, you are holding a time bomb here. Don't attack the messengers of bad news. Research the bad new to get familiar with the landscape.
This is truly a multidimentional "play" here. You have Private Equity bouncing these drugs between each other, making deals, stock swaps, IOUs etc.
Know what you own!
"karma has everyone's address"